2017 Migraine in America Symptoms and Treatment (MAST) Study: Gender Differences in Treatment Patterns and Unmet Treatment Needs (P3.145)

Objective: The objective of this abstract is to describe MAST study methods and provide initial data on gender differences in treatment patterns and areas of unmet need.

Background: The 2017 MAST study was conducted to understand migraine symptoms, treatment patterns and unmet needs.

Design/Methods: Respondents, ≥18 years, were recruited to the MAST Study from a nationwide online research panel, using stratified random sampling. Individuals meeting modified ICHD-3-beta criteria for migraine were identified using a validated screener. Respondents who averaged ≥1 headache day per month over the previous 3 months were included. Frequency data are provided along with chi-square contrasts (P<.05) comparing men with women.

Results: 117,150 individuals responded to an email survey, 15,133 met inclusion criteria for migraine and headache frequency. Mean age was 43.1 years, 73% were women, 81.0% were Caucasian, and 70.8% were employed. Among those reporting use of migraine prescription medication (n=4701), women were more likely than men to use triptans, barbiturates, and oral medications and men were more likely than women to use ergots, NSAIDs, opioids (Table 1, P< .05), and nasal and injectable medications (Table 1, P<.001). Women, compared to men, were more likely to report headache at awakening (44.1% vs 34.0%), not be pain free at 2 hours post-acute treatment (49.6% vs 45.1%), and experience recurrence within 24 hours of initial relief (40.8% vs 35.9%, Table 2, P<.01 for all). Pain relief (~60%) was comparable between genders. Men, compared to women, were more likely to report headache reaching peak intensity in <30 minutes, experiencing nausea with oral medications (17.1% vs 14.3%), and delaying treatment due to concerns about nausea (26.0% vs 23.0%, P<.05 for all).

Conclusions: Migraine medication classes used, their routes of administration, treatment outcomes and unmet treatment needs including poor treatment optimization and bothersome symptoms differ in men versus women.

Study Supported by: This study was funded and sponsored by the Dr. Reddy’s Laboratories group of companies, Princeton, NJ 08540, USA.

Disclosure: Dr. Alam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Reddy’s Laboratories group of companies. Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Has reviewed for the NIA and NINDS, serves as consultant, advisory board member, or has received honoraria from: Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmit. Dr. Lipton has received royalty, license fees, or contractual rights payments from Receives royalties from Wolff’s Headache, 8th Edition, Oxford University Press, 2009 and Informa. Dr. Lipton holds stock and/or stock options in Holds stock options in eNeura Therapeutics and Biohaven. Dr. Lipton has received research support from Support from the NIH, the Migraine Research Foundation, the National Headache Foundation, Allergan plc, Amgen, Dr Reddy’s, and Novartis. Dr. MUNJAL has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Reddy’s Laboratories group of companies. Dr. Buse has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Avanir, Amgen, Biohaven, Eli Lilly and Company and Promeius. Dr. Fanning has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Vedanta Research. Dr. Fanning has received research support from An employee of Vedanta Research, which has received research funding from Allergan, Amgen, Dr. Reddy’s Laboratories, Eli Lilly, GlaxoSmithKline, Merck & Co., Inc., and Novartis, via grants to the National Headache Foundation. Dr. Reed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Vedanta Research. Dr. Reed holds stock and/or stock options in Vedanta Research, which sponsored research in which Dr. Reed was involved as an investigator. Dr. Reed has received research support from Managing Director of Vedanta Research, which has received research funding from Allergan, Amgen, Dr. Reddy’s Laboratories, Eli Lilly, GlaxoSmithKline, Merck & Co., Inc., and Novartis, via grants to the National Headache Foundation. Vedanta Research ha. Dr. Schwedt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, ATI, Avanir, Dr. Reddy’s, Nocira, Novartis, Teva. Dr. Schwedt has received personal compensation in an editorial capacity for Headache, Pain Medicine, Cephalalgia. Dr. Dodick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Allergan, Amgen, Alder, Dr Reddy’s, Merck, Dr Reddy’s, Promius, eNeura, Eli Lilly & Company, Insys therapeutics, Autonomic Technologies, Teva, Xenon, Tonix, Trigemina, Boston Scientific, GBS, Colucid, Zosano, Laydenburg Thalmann, Biocentric, Biohaven, Magellan, Pfizer (Japan), Charleston Laboratories. Royalties: Oxford University Press and Cambridge University Press (Book Royalty). Uptodate — editorial/honoraria. CME companies honoraria/publishing honoraria/royalites: Chameleon Communications, Medscape, WebMD, Academy for Continued Healthcare Learning, Haymarket Medical Education, Miller Medical Communications, Global Scientific Communications, HealthLogix, Academy for Continued Healthcare Learning, Meeting LogiX, Health LogiX, .